We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Virtual Model Set to Boost Drug Development Efforts

By LabMedica International staff writers
Posted on 27 Mar 2018
A novel "physiome-on-a-chip" platform is expected to aid drug developers by combining several "organ-on-a-chip" nodes into an in vitro model of a functioning organism.

Microphysiological systems (MPSs) are in vitro models that capture facets of in vivo organ function through use of specialized culture microenvironments, including three-dimensional matrices and microperfusion. More...
To adapt MPS technology for purposes of drug development, investigators at the Massachusetts Institute of Technology (Cambridge, USA) developed a method to co-culture multiple different MPSs linked together physiologically on re-useable, open-system microfluidic platforms. Each MPS platform represented a different organ and was compatible with the quantitative study of a range of compounds, including lipophilic drugs.

The investigators adapted the physiome-on-a-chip platform from technology they had previously developed and commercialized through the biotechnology company CN BioInnovations (Welwyn Garden City, United Kingdom), The system incorporated several on-board pumps to control the flow of fluids between the "organs," on different nodes replicating the circulation of blood, immune cells, and proteins through the human body.

The investigators reported in the March 14, 2018, online edition of the journal Scientific Reports that they had created several versions of the chip, linking up to 10 organ types: liver, lung, gut, endometrium, brain, heart, pancreas, kidney, skin, and skeletal muscle. Each "organ" consisted of clusters of one million to two million cells.

"Animals do not represent people in all the facets that you need to develop drugs and understand disease," said senior author Dr. Linda Griffith, professor of biological and mechanical engineering at the Massachusetts Institute of Technology. "That is becoming more and more apparent as we look across all kinds of drugs. A lot of the time you do not see problems with a drug, particularly something that might be widely prescribed, until it goes on the market. Some of these effects are really hard to predict from animal models because the situations that lead to them are idiosyncratic. With our chip, you can distribute a drug and then look for the effects on other tissues and measure the exposure and how it is metabolized."

"An advantage of our platform is that we can scale it up or down and accommodate a lot of different configurations," said Dr. Griffith. "I think the field is going to go through a transition where we start to get more information out of a three-organ or four-organ system, and it will start to become cost-competitive because the information you are getting is so much more valuable."

Related Links:
Massachusetts Institute of Technology
CN BioInnovations


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.